For Immediate Release:
Molecular Response Hosts Webinar to Discuss Changing Paradigms in Oncology Drug Efficacy Studies
—-Proprietary platform combines world’s largest viable tumor bank with
3D ex vivo test systems and patient derived xenograft mouse models—
San Diego, CA – April 18, 2012 – Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in identification of target populations for high value therapeutics, today announced that it will host a webinar on October 9, 2012 to discuss the company’s proprietary drug testing platform, which combines 144,000 viable cryopreserved human tumor specimens, high content 3D ex vivo test systems and patient-derived xenograft (PDX) in vivo platforms.
To register for the webinar, visit: www.xenograft-webinar.com
The October 9th webinar will focus on use of patient-derived models to better understand drug response in a preclinical setting. The Molecular Repsonse platform enables use of the same patient material to create matched cell culture and animal models, enabling both ex vivo and in vivo studies in far more clinically relevant settings than previously possible using traditional cell lines in plastic dishes.
The webinar will focus on some of the key ex vivo 3D studies and in vivo PDX work performed at Molecular Response, including: target identification/validation, lead optimization, candidate selection, patient selection, combination agent approaches, and companion diagnostic development. Thomas Broudy, PhD, CSO and co-founder of Molecular Response will host the webinar.
“Our partners rely on our patient-derived models to make more confident decisions about their clinical strategy before actually going into the clinic,” said Broudy. “In a single study we might investigate a population of 20-50 patients using multiple test systems with multiple endpoints. That information affords an unprecedented understanding of drug response across a diverse population; as you might guess, we really think we have something novel and valuable to offer to the world of translational medicine.”
About Molecular Response
Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrating into existing pharmaceutical development processes and programs. Our results reduce risk and cost of drug development and allow for the most informed decisions with the best chance of success to advance therapeutic programs.
For additional information please visit www.molecularresponse.com
Lewis Vann, PhD